Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Variation In Prostate Stem Cell Antigen Gene Raises Bladder Cancer Risk
Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center.

Camera Phones Can Help Doctors Diagnose Uncommon Problems
Taking photographs or video of unusual symptoms on an ordinary camera phone can help doctors diagnose uncommon problems, say researchers in an article published on bmj.com.
News of the day
New Hope For Patients With Melanoma - The Most Deadly Form Of Skin Cancer And The Most Rapidly Increasing Cancer In The UK
Roche and Plexxikon announced interim results from a phase I study with PLX4032 (R7204) a new, highly selective and potentially promising oral treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation (known as mutation-positive). Patients treated with PLX4032 lived for a median of six months without their disease getting worse and more than half experienced significant shrinkage of their tumours; this included patients where the cancer had spread to the liver, lung and bone.1 Historically, less than 5% of metastatic melanoma patients are still alive five years after diagnosis.2
Cardiovascular

11th Tysabri Patient Develops PML

An 11th patient taking Biogen Idec"s multiple sclerosis (MS) drug Tysabri has developed a potentially deadly brain infection. In the latest confirmed case of progressive multifocal leukoencephalopathy, or PML, the patient took Tysabri for 29 doses, continuing the trend of the last six reported cases of the infection, where each patient had therapy for two years or longer. The latest patient was located in the USA, the third American to have developed the infection. Of the 11 reported cases, one patient has died. The PML incidence rate remains below the long-projected risk rate of one in 1,000 patients for those patients receiving the therapy for 12 months or 18 months. The drug was temporarily withdrawn in 2005 after it was linked with PML, but was then brought back in 2006 with stricter safety warnings. Tysabri continues to receive strong support from patients and doctors, however, because of the drug"s perceived effectiveness. That support has remained steady because patients are made well-aware of the PML risk before they start taking Tysabri for MS. This is the last case of PML that the company plans to announce on its website. In future any new cases will be reported by word of mouth to medical professional and patient groups. Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009